Signaturefd LLC Has $1.30 Million Holdings in Haleon plc (NYSE:HLN)

Signaturefd LLC grew its position in Haleon plc (NYSE:HLN) by 5.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 123,067 shares of the company’s stock after buying an additional 6,612 shares during the quarter. Signaturefd LLC’s holdings in Haleon were worth $1,302,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in HLN. AE Wealth Management LLC boosted its stake in Haleon by 6.1% in the 2nd quarter. AE Wealth Management LLC now owns 19,199 shares of the company’s stock worth $159,000 after purchasing an additional 1,098 shares during the period. Cardinal Capital Management grew its holdings in shares of Haleon by 2.5% during the second quarter. Cardinal Capital Management now owns 46,231 shares of the company’s stock valued at $382,000 after buying an additional 1,140 shares in the last quarter. Endowment Wealth Management Inc. raised its position in Haleon by 9.9% during the second quarter. Endowment Wealth Management Inc. now owns 12,867 shares of the company’s stock valued at $106,000 after buying an additional 1,161 shares during the period. Portside Wealth Group LLC lifted its stake in Haleon by 2.7% in the 2nd quarter. Portside Wealth Group LLC now owns 44,985 shares of the company’s stock worth $372,000 after acquiring an additional 1,182 shares in the last quarter. Finally, Hexagon Capital Partners LLC boosted its position in Haleon by 18.5% during the 3rd quarter. Hexagon Capital Partners LLC now owns 7,933 shares of the company’s stock worth $84,000 after acquiring an additional 1,238 shares during the period. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Price Performance

Shares of HLN opened at $9.90 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The firm has a market cap of $45.18 billion, a PE ratio of 32.98, a PEG ratio of 2.93 and a beta of 0.26. The firm’s 50 day moving average price is $10.23 and its 200 day moving average price is $9.18. Haleon plc has a twelve month low of $7.70 and a twelve month high of $10.80.

Haleon (NYSE:HLN) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $3.50 billion for the quarter, compared to the consensus estimate of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 13.15%. During the same quarter in the prior year, the business posted $0.08 EPS. As a group, research analysts expect that Haleon plc will post 0.47 EPS for the current fiscal year.

Haleon Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Stockholders of record on Friday, August 16th were paid a dividend of $0.0514 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio (DPR) is presently 33.33%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on HLN shares. Morgan Stanley upped their target price on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a report on Friday, September 20th. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Berenberg Bank began coverage on shares of Haleon in a report on Tuesday, August 6th. They set a “buy” rating on the stock. Finally, UBS Group upgraded Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.